Sarepta Therapeutics Inc
SRPT
Market Cap$1.97B
Close$
$153.22
712% upside
Current Fair Value
712% upsideUndervalued by 712% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.97 Billion |
|---|---|
| Enterprise Value | $3.20 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $2.34 |
| Beta | 0.6 |
| Outstanding Shares | 97,362,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.87 |
|---|---|
| PEG | 0.59 |
| Price to Sales | 0.86 |
| Price to Book Ratio | 1.72 |
| Enterprise Value to Revenue | 1.43 |
| Enterprise Value to EBIT | -16.35 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 1.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...